Latest research on Sensipar

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.

Latest findings

Cinacalcet (Mimpara, Sensipar, Amgen Inc., Thousand Oaks, USA) was initiated at 30 mg once daily with dinner. [source, 2015]
Some of the HDF patients were treated with cinacalcet (Mimpara, Amgen Dompè, Italy). [source, 2015]
For Risperdal and Mimpara, the number of drug packages sold in 2010 was provided by the pharmaceutical manufacturer (IMS Health sales figures) and the number of actual users was calculated indirectly based on the usual dosage prescribed (19). [source, 2014]
The introduction of cinacalcet (Mimpara) to the Swiss market resulted in a monetary loss compared to the standard treatment. [source, 2014]
As one drug (Mimpara) showed negative welfare effects, we cannot generally conclude that there is a positive welfare effect of new drugs compared to standard treatment. [source, 2014]
We also used cinacalcet (Sensipar) to bring down calcium. [source, 2014]
Cinacalcet (Sensipar), a calcimimetic drug, is available for the treatment of secondary hyperparathyroidism associated with renal failure, hypercalcemia in parathyroid cancer, and the treatment of severe hypercalcemia in patients with primary hyperparathyroidism unable to undergo parathyroidectomy [17–19]. [source, 2014]
Sixty-nine percent were already receiving low-dose oral Calcitriol (Rocaltrol, mainly given post-dialysis), 19% cinacalcet (Mimpara), and one patient intravenous Paricalcitol (Zemplar). [source, 2014]
Even after this second exploration, postoperatively the patient continued to experience hypercalcemia and was maintained on Sensipar and 1,25-OH Vitamin D. [source, 2013]
Yet, according to the information provided by the FDA (2012), postmarketing safety surveillance showed that “isolated, idiosyncratic cases of hypotension, and/or worsening heart failure have been reported in patients with impaired cardiac function, in which a causal relationship to Sensipar could not be completely excluded and may be mediated by reductions in serum calcium levels”. [source, 2013]